Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.

Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP, Besmer P.

Clin Cancer Res. 2004 May 15;10(10):3282-90.

2.

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.

Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.

Clin Cancer Res. 2007 Jan 1;13(1):170-81.

3.

Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.

Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV, Hagemeijer A, Sciot R.

Mod Pathol. 2004 Aug;17(8):889-94.

4.

Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.

Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P, Antonescu CR.

J Pediatr Hematol Oncol. 2005 Apr;27(4):179-87. Review.

PMID:
15838387
5.

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.

Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, Merkelbach-Bruse S, Schildhaus HU, Steigen SE, Stachura J, Wozniak A, Antonescu C, Daum O, Martin J, Del Muro JG, Miettinen M.

Mod Pathol. 2008 Apr;21(4):476-84. doi: 10.1038/modpathol.2008.2. Epub 2008 Feb 1.

6.

Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.

Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD.

J Clin Oncol. 2005 Apr 20;23(12):2735-43.

PMID:
15837988
7.

Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.

Allander SV, Nupponen NN, Ringnér M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG, Meltzer PS.

Cancer Res. 2001 Dec 15;61(24):8624-8.

8.

Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.

Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, Joensuu H, Isola J.

Scand J Gastroenterol. 2006 Jul;41(7):805-11.

PMID:
16785193
9.

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.

Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan MF, Ladanyi M, DeMatteo RP, Besmer P.

Clin Cancer Res. 2003 Aug 15;9(9):3329-37.

10.

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Zheng S, Chen LR, Wang HJ, Chen SZ.

Hepatogastroenterology. 2007 Dec;54(80):2285-90.

PMID:
18265649
11.

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.

Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M.

Lab Invest. 2004 Jul;84(7):874-83.

12.

Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.

Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki M, Steigen SE, Sarlomo-Rikala M, Boltze C, Kordek R, Roessner A, Stachura J, Miettinen M.

Mod Pathol. 2003 Dec;16(12):1257-64.

13.

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, Sciot R.

J Pathol. 2004 Apr;202(4):430-8.

PMID:
15095270
14.

Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors.

Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H, Hyung WJ, Noh SH, Kim JH, Yun CO, Liu ET, Kim H.

Oncogene. 2005 Feb 3;24(6):1066-74.

PMID:
15690055
15.

Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.

Miettinen M, Sobin LH, Lasota J.

Am J Surg Pathol. 2009 Sep;33(9):1267-75. doi: 10.1097/PAS.0b013e3181a13e99.

PMID:
19440146
16.

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.

Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR, Heinrich MC, Fletcher JA, van de Rijn M.

Oncogene. 2004 Oct 14;23(47):7780-90.

PMID:
15326474
17.

Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.

Cho S, Kitadai Y, Yoshida S, Tanaka S, Yoshihara M, Yoshida K, Chayama K.

Int J Oncol. 2006 Jun;28(6):1361-7.

PMID:
16685437
18.

Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y.

Thalheimer A, Schlemmer M, Bueter M, Merkelbach-Bruse S, Schildhaus HU, Buettner R, Hartung E, Thiede A, Meyer D, Fein M, Maroske J, Wardelmann E.

Am J Surg Pathol. 2008 Oct;32(10):1560-5. doi: 10.1097/PAS.0b013e318172ce6f.

PMID:
18724244
19.

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H.

J Clin Oncol. 2005 Jan 1;23(1):49-57. Epub 2004 Nov 15.

PMID:
15545668
20.

Supplemental Content

Support Center